Browse by Audience
Skip to content
Papers of the Week
An updated patent review of TRPA1 antagonists (2020 – present).
Authors
Vitale RM, de Petrocellis L, Amodeo PAbstract
TRPA1 is a nonselective calcium channel, member of the transient receptor potential (TRP) superfamily, also referred to as the ‘irritant’ receptor, being activated by pungent and noxious exogenous chemicals as well as by endogenous algogenic stimuli, to elicit pain, itch and inflammatory conditions. For this reason, it is considered an attractive therapeutic target to treat as wide range of diseases including acute and chronic pain, itch, and inflammatory airway diseases.